Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?

Bernie J. O[rsquo ]Brien, Andrew J. Willan, Gordon J. Blackhouse, Ron J. Goeree, Marc J. Cohen, Shaun J. Goodman

Open source

DOI
10.1067/mhj.2000.103552
Published
2000-03
Container
American Heart Journal
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1067/mhj.2000.103552,
  title = {Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?},
  author = {Bernie J. O[rsquo ]Brien and Andrew J. Willan and Gordon J. Blackhouse and Ron J. Goeree and Marc J. Cohen and Shaun J. Goodman},
  year = {2000},
  journal = {American Heart Journal},
  doi = {10.1067/mhj.2000.103552},
  url = {https://doi.org/10.1067/mhj.2000.103552}
}

RIS

TY  - JOUR
TI  - Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?
AU  - Bernie J. O[rsquo ]Brien
AU  - Andrew J. Willan
AU  - Gordon J. Blackhouse
AU  - Ron J. Goeree
AU  - Marc J. Cohen
AU  - Shaun J. Goodman
PY  - 2000
JO  - American Heart Journal
DO  - 10.1067/mhj.2000.103552
UR  - https://doi.org/10.1067/mhj.2000.103552
ER  - 

APA

]Brien, B. J. O., Willan, A. J., Blackhouse, G. J., Goeree, R. J., Cohen, M. J., & Goodman, S. J. (2000). Will the use of low-molecular-weight heparin (enoxaparin) in patients with acute coronary syndrome save costs in Canada?. American Heart Journal. https://doi.org/10.1067/mhj.2000.103552

Source records